Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

Axsome Therapeutics Joins Mental Health America and other Advocacy Organizations in Raising Awareness and Providing Support for Mental Health During Mental Health Month

GlobeNewswire May 7, 2021

Axsome Therapeutics to Report First Quarter 2021 Financial Results on May 10, 2021

GlobeNewswire April 27, 2021

Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder

GlobeNewswire April 26, 2021

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Axsome Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims

ACCESSWIRE IA April 24, 2021

Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

GlobeNewswire March 1, 2021

Axsome Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire February 19, 2021

Axsome Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021

GlobeNewswire February 16, 2021

Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer's Disease Agitation

GlobeNewswire December 31, 2020

Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine

GlobeNewswire December 31, 2020

Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation

GlobeNewswire December 8, 2020

Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression

GlobeNewswire December 2, 2020

Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder

GlobeNewswire December 1, 2020

Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 5, 2020

Axsome Therapeutics and Veeva Systems Partner to Build Axsome's Digital-Centric Commercialization(TM) Platform

Business Wire November 4, 2020

Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer's Disease Agitation at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference

GlobeNewswire November 3, 2020

Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020

GlobeNewswire October 28, 2020

Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital

GlobeNewswire September 29, 2020

Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine

GlobeNewswire September 24, 2020

Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting

GlobeNewswire September 21, 2020

Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation

GlobeNewswire September 17, 2020